FIELD: pharmaceuticals.
SUBSTANCE: invention relates to the crystalline form of 1-[2-(1-methylimidazol-4-yl)ethyl]perhydroazine-2,6-dione, characterized by the positions of the peaks in the powder X-ray diffraction pattern 2θ, deg.: 16.4±0.2 and 23.8± 0.2, as well as the method of its preparation, pharmaceutical composition and medicinal product based on it.
EFFECT: obtaining a new crystalline form of the compound which is stable, highly soluble, slightly hygroscopic, reduces the production of inflammatory cytokines and chemokines in a patient with acute respiratory viral infection and can be used in medicine for the treatment and/or prevention of viral diseases of the respiratory tract.
26 cl, 10 dwg, 4 tbl, 10 ex
